Investigating the effect of melatonin use versus placebo on delirium in patients admitted to the intensive care unit
Phase 3
Completed
- Conditions
- delirium.Other deliriumF05.8
- Registration Number
- IRCT20240429061595N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Age 18 and above
written and informed consent from the patient's legal guardian
Exclusion Criteria
Allergy to melatonin
intestinal obstruction
gastroparesis
side absorption
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie melatonin's potential anti-delirium effects in ICU patients?
How does melatonin compare to standard-of-care delirium treatments in ICU settings?
Are there specific biomarkers that predict melatonin responsiveness in delirium patients?
What are the potential adverse events associated with melatonin use in ICU patients?
What combination therapies or competitor drugs are being explored for delirium prevention in ICU patients?